Dana Pizzuti - Oct 1, 2025 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Med and Dev Officer
Signature
/s/ Tobin Schilke, as attorney-in-fact
Stock symbol
CRNX
Transactions as of
Oct 1, 2025
Transactions value $
-$124,600
Form type
4
Date filed
10/3/2025, 04:41 PM
Previous filing
Sep 4, 2025
Next filing
Nov 5, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Pizzuti Dana Chief Med and Dev Officer C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO /s/ Tobin Schilke, as attorney-in-fact 2025-10-03 0001948238

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Options Exercise $84.5K +5K +7.54% $16.89 71.3K Oct 1, 2025 Direct F1
transaction CRNX Common Stock Sale -$209K -5K -7.02% $41.81 66.3K Oct 1, 2025 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Stock Option (Right to Buy) Options Exercise $0 -5K -5.95% $0.00 79K Oct 1, 2025 Common Stock 5K $16.89 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 On September 4, 2025, the Reporting Person filed a Form 4 (the "Prior Form 4") which inadvertently reported that, following the transactions reported in the Prior Form 4, the Reporting Person directly owned 96,270 shares of the Issuer's common stock. In fact, the Reporting Person directly owned 66,270 shares of the Issuer's common stock following the transactions reported in the Prior Form 4.
F2 The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2025.
F3 The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $41.81 per share. The range of sales prices on the transaction date was $41.34 to $42.16 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request.
F4 The option is exercisable as follows: 25% of the shares subject to the option vested on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.